Recently, a large number of studies have focused on exploring the molecular biomarkers that could make up for the defects of the diagnosis of prostate specific antigen (PSA), so as to improve the positive rate of prostate biopsy and avoid unnecessary prostate biopsy for detecting the clinical significant high-grade PCa (10, 11). Here, PROS1 is linked to posterior cortical atrophy.